Press Releases See All 09/30/2024 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 09/30/2024 Sarepta Therapeutics Announces Recipients of LGMD Grant Awards for 2024; Program Supports Early Genetic Testing and Awareness 09/30/2024 Sarepta Therapeutics anuncia a los destinatarios de las subvenciones de 2024 para LGMD; el programa apoya las pruebas genéticas tempranas y la concientización Stories & Perspectives Filter by: Filter by: All Advocates & Innovators Culture & Community Inside the Science Patient Voices Filter by: AllAdvocates & InnovatorsCulture & CommunityInside the SciencePatient Voices Advocates & Innovators Navy veteran, lifelong learner, dedicated Duchenne Nurse Educator: Meet John Crane Inside the Science Wearable devices and the future of rare disease clinical trials: Landry’s story Advocates & Innovators Awards & Recognitions: Sarepta recognized for innovation and industry leadership Inside the Science Journey to better understanding of LGMD: Q&A on the early findings of a new natural history study Culture & Community Continuing a family legacy: Meet Sarepta colleague and Duchenne advocate Shawn Marlow Patient Voices When time is muscle: One dad shares his story to advocate for Duchenne newborn screening Advocates & Innovators Guardians of the last mile: Ensuring smooth delivery and a seamless patient experience Advocates & Innovators A tale of two interns: Meet Kate & Katherine, rare disease advocates and members of Sarepta’s Patient Affairs team Inside the Science What’s in a dose? Gene therapy dosing explained (Video) Advocates & Innovators Seeing hope at genetic medicine's frontier: Meet Stefanie Mason, M.D. Inside the Science Why are steroids used in gene therapy for neuromuscular disease? Advocates & Innovators A passion for patients, an influential mentor and a change in plans: Meet Danielle Griffin Patient Voices Creating pathways to LGMD genetic diagnosis: Spotlight on LGMD Grant Award recipient Advocates & Innovators Ensuring the safety of clinical trial participants: Meet Eddie Darton, M.D. Advocates & Innovators Dragging tomorrow into today: Meet Rachael Potter, Ph.D. Inside the Science Understanding external controls and their importance to clinical trials for rare diseases Inside the Science Meaningful measure: Understanding the NSAA, an important Duchenne functional-assessment tool Culture & Community What’d you do this summer? Our summer interns share lessons learned Culture & Community Pride proud: What belonging feels like and why representation matters Advocates & Innovators A conversation with CFO Ian Estepan, recipient of the 2022 CFO of the Year award from the Boston Business Journal Inside the Science Seroprevalence: What patients should know about pre-existing antibodies to gene therapy Inside the Science Patient registries: A catalyst for developing new therapies for rare diseases Inside the Science Measurements used in clinical trials for Duchenne muscular dystrophy – an overview Advocates & Innovators How a collaboration in the lab led to a seat at the table in Sarepta’s Gene Editing Innovation Center Culture & Community Giving thanks for our employees’ incredible dedication: Six employees explain why Sarepta is a Top Place to Work Inside the Science Welcome to GT‐FAQ! Advocates & Innovators Expanding access to newborn screening for those with rare diseases Patient Voices Patiently waiting Advocates & Innovators From art to science: How one Sarepta scientist brings arts into the lab Patient Voices Advocacy community unites to support families Culture & Community How Sarepta infused its corporate brand with urgency and optimism on behalf of patients Inside the Science What’s in a name? A lot, for the limb-girdle muscular dystrophy community. Media Library Sarepta Corporate Logos, Images & Fact Sheets View All Press Contact Tracy Sorrentino Executive Director, Public Relations Sarepta Therapeutics, Inc. [email protected] 617-274-4052
09/30/2024 Sarepta Therapeutics Announces Recipients of LGMD Grant Awards for 2024; Program Supports Early Genetic Testing and Awareness
09/30/2024 Sarepta Therapeutics anuncia a los destinatarios de las subvenciones de 2024 para LGMD; el programa apoya las pruebas genéticas tempranas y la concientización
Advocates & Innovators Navy veteran, lifelong learner, dedicated Duchenne Nurse Educator: Meet John Crane
Advocates & Innovators Awards & Recognitions: Sarepta recognized for innovation and industry leadership
Inside the Science Journey to better understanding of LGMD: Q&A on the early findings of a new natural history study
Culture & Community Continuing a family legacy: Meet Sarepta colleague and Duchenne advocate Shawn Marlow
Patient Voices When time is muscle: One dad shares his story to advocate for Duchenne newborn screening
Advocates & Innovators Guardians of the last mile: Ensuring smooth delivery and a seamless patient experience
Advocates & Innovators A tale of two interns: Meet Kate & Katherine, rare disease advocates and members of Sarepta’s Patient Affairs team
Advocates & Innovators A passion for patients, an influential mentor and a change in plans: Meet Danielle Griffin
Inside the Science Understanding external controls and their importance to clinical trials for rare diseases
Inside the Science Meaningful measure: Understanding the NSAA, an important Duchenne functional-assessment tool
Advocates & Innovators A conversation with CFO Ian Estepan, recipient of the 2022 CFO of the Year award from the Boston Business Journal
Inside the Science Seroprevalence: What patients should know about pre-existing antibodies to gene therapy
Inside the Science Measurements used in clinical trials for Duchenne muscular dystrophy – an overview
Advocates & Innovators How a collaboration in the lab led to a seat at the table in Sarepta’s Gene Editing Innovation Center
Culture & Community Giving thanks for our employees’ incredible dedication: Six employees explain why Sarepta is a Top Place to Work
Culture & Community How Sarepta infused its corporate brand with urgency and optimism on behalf of patients